Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The potential roles of metabolic syndrome (MetS) in the onset and progression of osteoarthritis (OA) have been a hot topic in the field since it may potentially open up to new non-surgical treatment regimens. To better study the relationship between MetS and OA, a suitable animal model would be a vital tool in understanding the pathomechanism and also for screening and testing various potential drug candidates.
We have recently read Deng and colleagues’ letter entitled ‘Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis’ published online this May, which mentioned the use of ‘obese spontaneously hypertensive heart failure’ (SHHFcp/cp) rat model to study MetS-associated OA and chronic administration of eplerenone, a mineralocorticoid receptor antagonist, as a treatment.1 While we appreciate the authors’ dedicated effort, we believe there are several …
Contributors PBC and CW equally contributed to this manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.